Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFC3XP)

• Drug Name: TBPS Drug Info
• Synonyms: tert-butylbicyclophosphorothionate

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 104781
  CAS Number: CAS 70636-86-1
  TTD Drug ID: DMFC3XP

Molecule-Related Drug Atlas

Drug(s) Targeting GABA(A) receptor gamma-2 (GABRG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Allopregnanolone	DMNLHAC	Depression	6A70-6A7Z	Approved	[15]
THIOCOLCHICOSIDE	DMEPWYA	Muscle spasm	MB47.3	Approved	[16]
ZK-93423	DMFWMKZ	Epileptic seizures	8A61-8A6Z	Phase 3	[17]
GSK683699	DMTW79H	Inflammatory bowel disease	DD72	Phase 2	[16]
ELTANOLONE	DM38CIV	Premenstrual syndrome	GA34.40	Discontinued in Phase 3	[15]
U-78875	DM2WOPX	Anxiety disorder	6B00-6B0Z	Discontinued in Phase 1	[18]
CGS-9896	DM39PQI	N. A.	N. A.	Terminated	[19]
CGS-17867A	DMMZJY3	Alcohol dependence	6C40.2	Terminated	[20]
AMENTOFLAVONE	DMLRNV2	Discovery agent	N.A.	Investigative	[21]
Ro-15-3505	DM4NW3U	Discovery agent	N.A.	Investigative	[22]

Drug(s) Targeting GABA(A) receptor rho3 (GABRR3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Isonipecotic acid	DMO1ZHE	Discovery agent	N.A.	Investigative	[13]
piperidine-4-sulphonic acid	DMMIZWE	Discovery agent	N.A.	Investigative	[13]
trans-3-ACPBPA	DM6HI8W	Discovery agent	N.A.	Investigative	[13]
cis-3-ACPBPA	DMQ0EA7	Discovery agent	N.A.	Investigative	[13]
5-Me-IAA	DMFZN7J	Discovery agent	N.A.	Investigative	[13]
aza-THIP	DML70NC	Discovery agent	N.A.	Investigative	[13]
TPMPA	DMBF6KS	Discovery agent	N.A.	Investigative	[13]
(+/-)-cis-2-CAMP	DMY3J0B	Discovery agent	N.A.	Investigative	[13]

Drug(s) Targeting GABA(A) receptor alpha-5 (GABRA5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flumazenil	DMPCG2L	Benzodiazepine overdose	PC91	Approved	[4]
GSK683699	DMTW79H	Inflammatory bowel disease	DD72	Phase 2	[23]
Basmisanil	DMQ8J0U	Alzheimer disease	8A20	Phase 2	[24]
RG-7816	DMD16JK	Autism spectrum disorder	6A02	Phase 1	[25]
AMENTOFLAVONE	DMLRNV2	Discovery agent	N.A.	Investigative	[21]
Ro-15-3505	DM4NW3U	Discovery agent	N.A.	Investigative	[26]
Isonipecotic acid	DMO1ZHE	Discovery agent	N.A.	Investigative	[4]
[3H]Ro154513	DMMBWKL	Discovery agent	N.A.	Investigative	[27]
[3H]CGS8216	DMLP68J	Inflammation	1A00-CA43.1	Investigative	[4]
CI-218872	DM0RH3S	Discovery agent	N.A.	Investigative	[28]

Drug(s) Targeting GABA(A) receptor delta (GABRD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Allopregnanolone	DMNLHAC	Depression	6A70-6A7Z	Approved	[25]
Gaboxadol	DMI53FU	Insomnia	7A00-7A0Z	Approved	[29]
Ganaxolone	DMXJMKF	Complex partial seizure	8A68.0	Phase 3	[30]
SAGE-217b	DMRFK0B	Major depressive disorder	6A70.3	Phase 2	[25]
PF-4480682	DMWYJHC	Neuropathic pain	8E43.0	Discontinued in Phase 2	[31]
PF-2393296	DM5R2MG	Neuropathic pain	8E43.0	Discontinued in Phase 1	[6]
Co-60549	DMGIZHX	Anxiety disorder	6B00-6B0Z	Terminated	[32]
Org-20599	DMQU8AR	Anaesthesia	9A78.6	Terminated	[33]
RU-5135	DMCASRD	Discovery agent	N.A.	Investigative	[34]

Drug(s) Targeting GABA(A) receptor gamma-3 (GABRG3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zolpidem	DMWOSKJ	Insomnia	7A00-7A0Z	Approved	[9]
Allopregnanolone	DMNLHAC	Depression	6A70-6A7Z	Approved	[24]
Clobazam - Lundbeck	DMW1OQ0	Anxiety disorder	6B00-6B0Z	Approved	[35]
Flumazenil	DMPCG2L	Benzodiazepine overdose	PC91	Approved	[9]
Stiripentol	DMMSDOY	Dravet syndrome	8A61.11	Approved	[36]
Thiamylal	DMHDF7B	Anaesthesia	9A78.6	Approved	[35]
Mebutamate	DM0KYI4	Anxiety disorder	6B00-6B0Z	Approved	[35]
Metharbital	DM5A38V	Epilepsy	8A60-8A68	Approved	[35]
Etomidate	DMZI3WO	Anaesthesia	9A78.6	Approved	[35]
Remimazolam	DMLVSYX	Procedural sedation	JB0C.3	Approved	[37]

Drug(s) Targeting GABA(A) receptor alpha-2 (GABRA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flumazenil	DMPCG2L	Benzodiazepine overdose	PC91	Approved	[2]
GSK683699	DMTW79H	Inflammatory bowel disease	DD72	Phase 2	[23]
PF-4480682	DMWYJHC	Neuropathic pain	8E43.0	Discontinued in Phase 2	[31]
CGS-17867A	DMMZJY3	Alcohol dependence	6C40.2	Terminated	[20]
AMENTOFLAVONE	DMLRNV2	Discovery agent	N.A.	Investigative	[21]
Ro-15-3505	DM4NW3U	Discovery agent	N.A.	Investigative	[26]
Isonipecotic acid	DMO1ZHE	Discovery agent	N.A.	Investigative	[2]
[3H]Ro154513	DMMBWKL	Discovery agent	N.A.	Investigative	[27]
[3H]CGS8216	DMLP68J	Inflammation	1A00-CA43.1	Investigative	[2]
CI-218872	DM0RH3S	Discovery agent	N.A.	Investigative	[28]

Drug(s) Targeting GABA(A) receptor alpha-3 (GABRA3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flumazenil	DMPCG2L	Benzodiazepine overdose	PC91	Approved	[3]
GSK683699	DMTW79H	Inflammatory bowel disease	DD72	Phase 2	[23]
Adipiplon	DM821BS	Sleep-wake disorder	7A00-7B2Z	Phase 2	[38]
NS-2710	DMMUR6V	Anxiety disorder	6B00-6B0Z	Phase 2	[39]
AZD6280	DMFAZLU	Anxiety disorder	6B00-6B0Z	Discontinued in Phase 1	[40]
AMENTOFLAVONE	DMLRNV2	Discovery agent	N.A.	Investigative	[21]
Ro-15-3505	DM4NW3U	Discovery agent	N.A.	Investigative	[26]
Isonipecotic acid	DMO1ZHE	Discovery agent	N.A.	Investigative	[3]
[3H]Ro154513	DMMBWKL	Discovery agent	N.A.	Investigative	[27]
[3H]CGS8216	DMLP68J	Inflammation	1A00-CA43.1	Investigative	[3]

Drug(s) Targeting GABA(A) receptor beta-2 (GABRB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Allopregnanolone	DMNLHAC	Depression	6A70-6A7Z	Approved	[15]
THIOCOLCHICOSIDE	DMEPWYA	Muscle spasm	MB47.3	Approved	[16]
Ethchlorvynol	DM53IP1	Insomnia	7A00-7A0Z	Approved	[41]
ZK-93423	DMFWMKZ	Epileptic seizures	8A61-8A6Z	Phase 3	[17]
GSK683699	DMTW79H	Inflammatory bowel disease	DD72	Phase 2	[16]
ELTANOLONE	DM38CIV	Premenstrual syndrome	GA34.40	Discontinued in Phase 3	[15]
U-78875	DM2WOPX	Anxiety disorder	6B00-6B0Z	Discontinued in Phase 1	[42]
CGS-9896	DM39PQI	N. A.	N. A.	Terminated	[19]
AMENTOFLAVONE	DMLRNV2	Discovery agent	N.A.	Investigative	[21]
Ro-15-3505	DM4NW3U	Discovery agent	N.A.	Investigative	[22]

Drug(s) Targeting GABA(A) receptor rho2 (GABRR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Isonipecotic acid	DMO1ZHE	Discovery agent	N.A.	Investigative	[12]
piperidine-4-sulphonic acid	DMMIZWE	Discovery agent	N.A.	Investigative	[12]
trans-3-ACPBPA	DM6HI8W	Discovery agent	N.A.	Investigative	[12]
cis-3-ACPBPA	DMQ0EA7	Discovery agent	N.A.	Investigative	[12]
5-Me-IAA	DMFZN7J	Discovery agent	N.A.	Investigative	[12]
aza-THIP	DML70NC	Discovery agent	N.A.	Investigative	[12]
TPMPA	DMBF6KS	Discovery agent	N.A.	Investigative	[12]
(+/-)-cis-2-CAMP	DMY3J0B	Discovery agent	N.A.	Investigative	[12]

Drug(s) Targeting GABA(A) receptor rho1 (GABRR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Isonipecotic acid	DMO1ZHE	Discovery agent	N.A.	Investigative	[11]
piperidine-4-sulphonic acid	DMMIZWE	Discovery agent	N.A.	Investigative	[11]
trans-3-ACPBPA	DM6HI8W	Discovery agent	N.A.	Investigative	[11]
cis-3-ACPBPA	DMQ0EA7	Discovery agent	N.A.	Investigative	[11]
5-Me-IAA	DMFZN7J	Discovery agent	N.A.	Investigative	[11]
aza-THIP	DML70NC	Discovery agent	N.A.	Investigative	[11]
TPMPA	DMBF6KS	Discovery agent	N.A.	Investigative	[11]
(+/-)-cis-2-CAMP	DMY3J0B	Discovery agent	N.A.	Investigative	[11]
CACA	DMPKFYZ	Discovery agent	N.A.	Investigative	[43]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
GABA(A) receptor alpha-2 (GABRA2)	TTBMV1G	GBRA2_HUMAN	Blocker (channel blocker)	[2]
GABA(A) receptor alpha-3 (GABRA3)	TT37EDJ	GBRA3_HUMAN	Blocker (channel blocker)	[3]
GABA(A) receptor alpha-5 (GABRA5)	TTNZPQ1	GBRA5_HUMAN	Blocker (channel blocker)	[4]
GABA(A) receptor beta-2 (GABRB2)	TTZA1NY	GBRB2_HUMAN	Blocker (channel blocker)	[5]
GABA(A) receptor delta (GABRD)	TTGXH6N	GBRD_HUMAN	Blocker (channel blocker)	[6]
GABA(A) receptor epsilon (GABRE)	TTBY4OD	GBRE_HUMAN	Blocker (channel blocker)	[7]
GABA(A) receptor gamma-2 (GABRG2)	TT06RH5	GBRG2_HUMAN	Blocker (channel blocker)	[8]
GABA(A) receptor gamma-3 (GABRG3)	TTEX6LM	GBRG3_HUMAN	Blocker (channel blocker)	[9]
GABA(A) receptor pi (GABRP)	TT3E0DI	GBRP_HUMAN	Blocker (channel blocker)	[10]
GABA(A) receptor rho1 (GABRR1)	TT6XFEU	GBRR1_HUMAN	Blocker (channel blocker)	[11]
GABA(A) receptor rho2 (GABRR2)	TTQMXLS	GBRR2_HUMAN	Blocker (channel blocker)	[12]
GABA(A) receptor rho3 (GABRR3)	TT4N6D8	GBRR3_HUMAN	Blocker (channel blocker)	[13]
GABA(A) receptor theta (GABRQ)	TTXDUR9	GBRT_HUMAN	Blocker (channel blocker)	[14]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4320).
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 405).
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 406).
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 408).
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 411).
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 416).
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 417).
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 414).
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415).
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 419).
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 420).
• [12] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 421).
• [13] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 422).
• [14] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 418).
• [15] Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (... J Med Chem. 2005 Apr 21;48(8):3051-9.
• [16] 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
• [17] Structural requirements for agonist actions at the benzodiazepine receptor: studies with analogues of 6-(benzyloxy)-4-(methoxymethyl)-beta-carbolin... J Med Chem. 1990 Mar;33(3):1062-9.
• [18] 3-Phenyl-substituted imidazo[1,5-alpha]quinoxalin-4-ones and imidazo[1,5-alpha]quinoxaline ureas that have high affinity at the GABAA/benzodiazepin... J Med Chem. 1996 Sep 13;39(19):3820-36.
• [19] Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors. J Med Chem. 2006 Mar 23;49(6):1855-66.
• [20] 2,5-Dihydropyrazolo[4,3-c]pyridin-3-ones: functionally selective benzodiazepine binding site ligands on the GABAA receptor. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3441-4.
• [21] Semisynthetic preparation of amentoflavone: A negative modulator at GABA(A) receptors. Bioorg Med Chem Lett. 2003 Jul 21;13(14):2281-4.
• [22] Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6.
• [23] New anticonvulsants: Schiff bases of gamma-aminobutyric acid and gamma-aminobutyramide. J Med Chem. 1980 Jun;23(6):702-4.
• [24] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [25] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [26] The GABA(A) receptor as a target for photochromic molecules. Bioorg Med Chem. 2010 Nov 15;18(22):7731-8.
• [27] Synthesis and pharmacological properties of novel 8-substituted imidazobenzodiazepines: high-affinity, selective probes for alpha 5-containing GABA... J Med Chem. 1996 Apr 26;39(9):1928-34.
• [28] Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
• [29] Gaboxadol--a new awakening in sleep.Curr Opin Pharmacol.2006 Feb;6(1):30-6.
• [30] Ganaxolone, a selective, high-affinity steroid modulator of the gamma-aminobutyric acid-A receptor, exacerbates seizures in animal models of absence. Ann Neurol. 1998 Oct;44(4):688-91.
• [31] WO patent application no. 2014,1515,17, Methods of improving microvascular integrity.
• [32] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007012)
• [33] The anaesthetic action and modulation of GABAA receptor activity by the novel water-soluble aminosteroid Org 20599. Neuropharmacology. 1996;35(9-10):1209-22.
• [34] Complex interactions between the steroid derivative RU 5135 and the GABAA-receptor complex. Eur J Pharmacol. 1992 Oct 1;227(2):147-51.
• [35] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [36] Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA-A receptor channels. Epilepsia. 2006 Apr;47(4):704-16.
• [37] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [38] Discriminative stimulus properties of GABAA receptor positive allosteric modulators TPA023, ocinaplon and NG2-73 in rats trained to discriminate chlordiazepoxide or zolpidem. Eur J Pharmacol. 2011 Oct 1;668(1-2):190-3.
• [39] GABAA receptor subtype-selective modulators. I. alpha2/alpha3-selective agonists as non-sedating anxiolytics. Curr Top Med Chem. 2011;11(9):1176-202.
• [40] AZD6280, a novel partial -aminobutyric acid A receptor modulator, demonstrates a pharmacodynamically selective effect profile in healthy male volunteers.J Clin Psychopharmacol.2015 Feb;35(1):22-33.
• [41] DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
• [42] High-affinity alpha-aminobutyric acid A/benzodiazepine ligands: synthesis and structure-activity relationship studies of a new series of tetracycli... J Med Chem. 1996 Nov 8;39(23):4654-66.
• [43] Characterization of bicuculline/baclofen-insensitive (rho-like) gamma-aminobutyric acid receptors expressed in Xenopus oocytes. II. Pharmacology of gamma-aminobutyric acidA and gamma-aminobutyric acidB receptor agonists and antagonists. Mol Pharmacol. 1993 Apr;43(4):609-25.